Melanoma Clinical Trials

Showing 641-660 of 1,292 trials

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

NCT04430842

This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.

AstrocytomaBrain CancerBrain Metastases+20 more

Quadriga Biosciences, Inc.15 participantsStarted Jul 2020

Kogarah, New South Wales, Australia • Liverpool, New South Wales, Australia

RECRUITING

Registry of Subjects at Risk of Pancreatic Cancer

NCT04095195

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Familial Pancreatic CancerBRCA1 MutationBRCA2 Mutation+4 more

Associazione Italiana per lo Studio del Pancreas1,000 participantsStarted Aug 2019

Rozzano, Milan, Italy • Peschiera del Garda, Verona, Italy • Milan, Italy +1 more locations

COMPLETED

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

NCT03843593

The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.

Cutaneous Melanoma

Memorial Sloan Kettering Cancer Center38 participantsStarted Feb 2019

Basking Ridge, New Jersey, United States • Harrison, New York, United States • New York, New York, United States

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Registry of Subjects at Risk of Pancreatic Cancer

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Related Searches

MRI and PET to Assess Pembrolizumab Response

Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Virtual Sun Safe Workplaces Ph I

A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors